Phibro Animal Health Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share. The dividend applies to both its Class A and Class B common stock. It will be paid on June 24, 2026 to stockholders of record as of the close of business on June 3, 2026.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on April 28–30, 2026. The weighted average sale prices ranged from about $52.65 to $56.69 per share, with all sales executed under a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025. Following these sales, BFI’s reported indirect holdings were 74,760 shares, and Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corporation entered into Amendment No. 1 to its Credit Agreement with Coöperatieve Rabobank U.A. and other lenders on April 28, 2026. This amendment increases the company’s revolving credit commitment by $125,000,000, raising the facility from $310,000,000 to an aggregate commitment of $435,000,000.
The larger revolving credit line represents a new direct financial obligation for Phibro and is documented as a material definitive agreement. The full text of Amendment No. 1 is filed as Exhibit 10.1 and is incorporated by reference for detailed terms, representations and warranties.
Phibro Animal Health Corp reports institutional ownership disclosure. Vanguard Capital Management reports beneficial ownership of 1,043,822 shares, representing 5.06% of common stock as of 03/31/2026. The filing attributes 152,539 shares of sole voting power and 1,043,822 shares of sole dispositive power to Vanguard Capital Management and affiliated business divisions.
Phibro Animal Health Corporation describes a new Brazilian rule that will phase out growth-promotion uses of certain antimicrobial feed additives, including its virginiamycin and bacitracin products. Brazil’s Ministry of Agriculture and Livestock published Ordinance No. 1617, which bans the import, manufacture, marketing and use of these performance-enhancing additives.
The prohibition takes effect after a 180-day transition period, during which current products and labels may still be used and sold. Phibro is pursuing new registrations of virginiamycin for therapeutic use in cattle and broiler chickens and notes its bacitracin product already has therapeutic claims in Brazil. Under the new framework, future use of these antimicrobials will require a veterinary prescription, and Phibro is introducing its PhibroVet digital platform in Brazil to help manage prescriptions. The company expects this regulatory change to have limited impact on its fiscal year 2026 results and plans to provide further detail on its May 7, 2026 earnings call.
BFI Co., LLC and Jack C. Bendheim report updated ownership of Phibro Animal Health Corporation Class A Common Stock in an Amendment No. 24 to Schedule 13D. They beneficially own 19,591,914 shares of Common Stock, representing 48.3% of the Class A Common Stock on an as-converted basis.
BFI directly holds 95,880 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock, which is convertible into Class A on a one-for-one basis and carries ten votes per share. The filing notes market disposals of Class A shares within the prior 60 days, detailed in an exhibit.
Phibro Animal Health reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open‑market transactions at weighted average prices around $54–$56 per share. These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025. After the sales, BFI Co., LLC held 95,880 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health Corp’s CEO-linked entity BFI Co., LLC converted 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock and then sold 21,120 Class A shares in open-market transactions from April 14–16 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices ranged from about $53.80 to $59.83. After these trades, BFI held 117,000 Class A shares indirectly, while Jack Bendheim also directly held 16,840 Class A shares, showing that a substantial position remains after these planned sales.
Phibro Animal Health Corporation reported that board member Joyce J. Lee, a Class II Director, informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The company stated that Ms. Lee’s resignation is not due to any disagreement regarding its operations, policies, or practices.
FMR LLC reported beneficial ownership of 2,173,126.20 shares of PHIBRO ANIMAL HEALTH CORP Class A common stock, representing 10.5% of the class as of 03/31/2026. The filing states FMR has sole voting power over 2,171,187 shares and sole dispositive power over 2,173,126.20 shares. The Schedule 13G notes some shares are held on behalf of other persons and refers to Exhibit 99 for a 13d-1(k)(1) agreement.